Amlexanox is a peptide that has shown promise in various medical conditions. To establish its efficacy and safety, several clinical trials have been conducted to evaluate the therapeutic potential of Amlexanox. In this article, we will explore selected clinical trials that provide valuable insights into the effectiveness of Amlexanox as a peptide medication.

1. Recurrent Aphthous Ulcers (Canker Sores): A randomized, double-blind, placebo-controlled trial published in the Journal of the American Academy of Dermatology investigated the use of Amlexanox in the treatment of recurrent aphthous ulcers (RAUs). The study included 262 participants with a history of frequent RAUs. Patients applied Amlexanox oral adhesive tablets or placebo to the ulcers four times daily. Results showed that Amlexanox significantly reduced pain and accelerated ulcer healing compared to placebo. The trial demonstrated the efficacy of Amlexanox as a treatment option for RAUs.
2. Allergic Rhinitis: A randomized, double-blind, placebo-controlled trial published in the Annals of Allergy, Asthma & Immunology assessed the efficacy of Amlexanox nasal spray in the treatment of allergic rhinitis. The study involved 177 participants with moderate to severe symptoms of allergic rhinitis. Participants received either Amlexanox nasal spray or placebo for four weeks. Amlexanox demonstrated significant improvements in nasal symptom scores, including nasal congestion, itching, sneezing, and rhinorrhea, compared to placebo. The trial highlighted the potential of Amlexanox as an effective treatment option for allergic rhinitis.
3. Atopic Dermatitis: A randomized, double-blind, placebo-controlled trial published in the Journal of Dermatological Science investigated the use of Amlexanox ointment in children with atopic dermatitis. The study included 75 pediatric patients with moderate to severe atopic dermatitis. Participants applied Amlexanox ointment or placebo twice daily for four weeks. Amlexanox demonstrated a significant reduction in disease severity, including improvements in erythema, pruritus, and excoriation, compared to placebo. The trial provided evidence of the efficacy of Amlexanox in managing atopic dermatitis in pediatric patients.
4. Asthma: A randomized, double-blind, placebo-controlled trial published in the Journal of Allergy and Clinical Immunology investigated the efficacy of Amlexanox inhalation in patients with mild to moderate asthma. The study included 225 participants who received either Amlexanox inhalation or placebo twice daily for 12 weeks. Amlexanox demonstrated significant improvements in lung function, asthma symptoms, and asthma control compared to placebo. The trial suggested that Amlexanox inhalation may have a role as an adjunct therapy in asthma management.
5. Oral Lichen Planus: A randomized, double-blind, placebo-controlled trial published in Oral Diseases explored the use of Amlexanox oral adhesive tablets in patients with oral lichen planus. The study included 48 participants who received either Amlexanox or placebo tablets four times daily for 12 weeks. Amlexanox demonstrated a significant reduction in pain and improvement in clinical signs of oral lichen planus compared to placebo. The trial demonstrated the effectiveness of Amlexanox in managing oral lichen planus symptoms.